Cancer-associated thrombosis

被引：143

作者：

Zwicker, Jeffrey I. ^{[1
]}

Furie, Barbara C.

Furie, Bruce

机构：

[1] Beth Israel Deaconess Med Ctr, Ctr Hemostasis & Thrombosis Res, Boston, MA 02215 USA

[2] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2007年 / 62卷 / 02期

关键词：

venous thromboembolic events (VTE); malignancy; cancer thrombosis; DEEP-VEIN THROMBOSIS; TUMOR-NECROSIS-FACTOR; FACTOR-V-LEIDEN; PLASMINOGEN-ACTIVATOR INHIBITOR-1; VON-WILLEBRAND-FACTOR; PLATELET-DERIVED MICROPARTICLES; TISSUE FACTOR EXPRESSION; ENDOTHELIAL GROWTH-FACTOR; CENTRAL VENOUS LINE; LEUKEMIA-CELL-LINE;

D O I：

10.1016/j.critrevonc.2007.01.001

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

There is strong evidence linking venous thromboembolic events and malignancy. Laboratory markers of coagulation activation such as thrombin-antithrombin complex or prothrombin fragments 1 + 2 support the premise that malignancy is a hypercoagulable state. Inflammatory cytokines (e.g. tumor necrosis factor and interferon-gamma), coagulation proteins (e.g. tissue factor and factor VIII), and procoagulant microparticles may be elevated in patients with malignancy. However, the molecular basis for cancer associated thrombosis remains unknown and the relative contribution of chemotherapeutics, tumor cells, endothelium, and circulating procoagulants in promoting thrombus formation continues to be investigated. (c) 2007 Elsevier Ireland Ltd. All rights reserved.

引用

页码：126 / 136

页数：11

共 155 条

[1] Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor [J].

Abe, K ;

Shoji, M ;

Chen, J ;

Bierhaus, A ;

Danave, I ;

Micko, C ;

Casper, K ;

Dillehay, DL ;

Nawroth, PP ;

Rickles, FR .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (15) :8663-8668

[2] Phase II study of sorafenib in patients with advanced hepatocellular carcinoma [J].

Abou-Alfa, Ghassan K. ;

Schwartz, Lawrence ;

Ricci, Sergio ;

Amadori, Dino ;

Santoro, Armando ;

Figer, Arie ;

De Greve, Jacques ;

Douillard, Jean-Yves ;

Lathia, Chetan ;

Schwartz, Brian ;

Taylor, Ian ;

Moscovici, Marius ;

Saltz, Leonard B. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (26) :4293-4300

[3]

AMBRUS JL, 1975, J MED, V6, P61

[4] Circulating platelet-derived microparticles with procoagulant activity may be a potential cause of thrombosis in uremic patients [J].

Ando, M ;

Iwata, A ;

Ozeki, Y ;

Tsuchiya, K ;

Akiba, T ;

Nihei, H .

KIDNEY INTERNATIONAL, 2002, 62 (05) :1757-1763

[5]

ANDRENSANDBERG A, 1992, CANCER-AM CANCER SOC, V69, P2884, DOI 10.1002/1097-0142(19920615)69:12<2884::AID-CNCR2820691204>3.0.CO

[6]

2-S

[7] Induction of microparticle- and cell-associated intravascular tissue factor in human endotoxemia [J].

Aras, O ;

Shet, A ;

Bach, RR ;

Hysjulien, JL ;

Slungaard, A ;

Hebbel, RP ;

Escolar, G ;

Jilma, B ;

Key, NS .

BLOOD, 2004, 103 (12) :4545-4553

[8]

Barbui T, 1996, THROMB HAEMOSTASIS, V75, P368

[9]

BASTIDA E, 1984, BLOOD, V64, P177

[10] The incidence of occult cancer in patients with deep venous thrombosis: A prospective study [J].

Bastounis, EA ;

Karayiannakis, AJ ;

Makri, GG ;

Alexiou, D ;

Papalambros, EL .

JOURNAL OF INTERNAL MEDICINE, 1996, 239 (02) :153-156

← 1 2 3 4 5 6 7 8 9 10 →